Studies have focused on energy homeostasis, body composition and metabolic pathway modulation via simultaneous incretin and glucagon engagement
1 Depending on the specific molecules half-life, GLP-1 medications can also have a short-release or extended-release action, determining how long their effects last in the body
The study, as reported in the New England Journal of Medicine, varied the dosages administered, noting the highest weight loss at the largest dosage
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Weight loss and physical activity changes: Patients achieving significant weight loss with GLP-1 therapy may experience changes in exercise tolerance and breathing patterns
Figure 30: Photograph of Professor Sir Stephen Bloom, 2013, credit: Bloom